• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

SMARCA4缺陷型非小细胞肺癌:临床人口统计学、计算机断层扫描及正电子发射断层扫描-计算机断层扫描特征

SMARCA4-deficient non-small cell lung carcinoma: clinicodemographic, computed tomography, and positron emission tomography-computed tomography features.

作者信息

Kim Jong Hee, Woo Jung Han, Lim Chae Young, An Taein, Han Joungho, Chung Myung Jin, Cha Yoon Ki

机构信息

Department of Radiology and Center for Imaging Science, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.

Department of Pathology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.

出版信息

J Thorac Dis. 2024 Mar 29;16(3):1753-1764. doi: 10.21037/jtd-23-1606. Epub 2024 Mar 8.

DOI:10.21037/jtd-23-1606
PMID:38617754
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11009581/
Abstract

BACKGROUND

SMARCA4-deficient non-small cell lung carcinoma (SD-NSCLC) is a relatively rare tumor, which occurs in 5-10% of NSCLC. Based on World Health Organization thoracic tumor classification system, SMARCA4-deficient undifferentiated tumor (SD-UT) is recognized as a separate entity from SD-NSCLC. Differentiation between SD-NSCLC and SD-UT is often difficult due to shared biological continuum, but often required for choosing appropriate treatment regimen. Therefore, the aim of our study was to identify the clinicopathologic, computed tomography (CT), and positron emission tomography (PET)-CT imaging features of SD-NSCLC.

METHODS

Nine patients of pathologically confirmed SD-NSCLC were included in our analysis. We reviewed electronic medical records for clinical information, demographic features, CT, and PET-CT imaging features were analyzed.

RESULTS

Smoking history and male predominance are observed in all patients with SD-NSCLC (n=9). On CT, SD-NSCLC appeared as relatively well-defined masses with lobulated contour (n=8) and peripheral location (n=7). Invasion of adjacent pleura or chest wall (n=7) were frequently observed, regardless of small tumor size. Four cases showed lymph node metastases. Among nine patients, three patients showed multiple bone metastases, and one patient showed lung-to-lung metastases.

CONCLUSIONS

In patient with SD-NSCLC, there was tendency for male smokers, peripheral location and invasion of adjacent pleural or chest wall invasion regardless of small tumor size, when compared to SD-UT.

摘要

背景

SMARCA4缺陷型非小细胞肺癌(SD-NSCLC)是一种相对罕见的肿瘤,占非小细胞肺癌的5%-10%。根据世界卫生组织胸肿瘤分类系统,SMARCA4缺陷型未分化肿瘤(SD-UT)被认为是与SD-NSCLC不同的实体。由于存在共同的生物学连续性,SD-NSCLC与SD-UT的鉴别往往困难,但这对于选择合适的治疗方案通常是必需的。因此,我们研究的目的是确定SD-NSCLC的临床病理、计算机断层扫描(CT)和正电子发射断层扫描(PET)-CT成像特征。

方法

我们纳入了9例经病理证实的SD-NSCLC患者进行分析。我们查阅电子病历以获取临床信息,分析人口统计学特征、CT及PET-CT成像特征。

结果

所有SD-NSCLC患者(n=9)均有吸烟史且以男性为主。CT表现上,SD-NSCLC表现为边界相对清晰的肿块,呈分叶状轮廓(n=8)且位于周边(n=7)。无论肿瘤大小,均常见侵犯相邻胸膜或胸壁(n=7)。4例出现淋巴结转移。9例患者中,3例出现多发骨转移,1例出现肺内转移。

结论

与SD-UT相比,SD-NSCLC患者倾向于男性吸烟者、肿瘤位于周边且无论肿瘤大小均易侵犯相邻胸膜或胸壁。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b771/11009581/037e7c2cdf74/jtd-16-03-1753-f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b771/11009581/b5235c9b62e9/jtd-16-03-1753-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b771/11009581/037e7c2cdf74/jtd-16-03-1753-f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b771/11009581/b5235c9b62e9/jtd-16-03-1753-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b771/11009581/037e7c2cdf74/jtd-16-03-1753-f2.jpg

相似文献

1
SMARCA4-deficient non-small cell lung carcinoma: clinicodemographic, computed tomography, and positron emission tomography-computed tomography features.SMARCA4缺陷型非小细胞肺癌:临床人口统计学、计算机断层扫描及正电子发射断层扫描-计算机断层扫描特征
J Thorac Dis. 2024 Mar 29;16(3):1753-1764. doi: 10.21037/jtd-23-1606. Epub 2024 Mar 8.
2
Thoracic SMARCA4-deficient tumors: a clinicopathological analysis of 52 cases with SMARCA4-deficient non-small cell lung cancer and 20 cases with thoracic SMARCA4-deficient undifferentiated tumor.胸段SMARCA4缺陷型肿瘤:52例SMARCA4缺陷型非小细胞肺癌及20例胸段SMARCA4缺陷型未分化肿瘤的临床病理分析
PeerJ. 2024 Feb 16;12:e16923. doi: 10.7717/peerj.16923. eCollection 2024.
3
Promising efficacy of immune checkpoint inhibitor plus chemotherapy for thoracic SMARCA4-deficient undifferentiated tumor.免疫检查点抑制剂联合化疗治疗胸部 SMARCA4 缺陷型未分化肿瘤的疗效有希望。
J Cancer Res Clin Oncol. 2023 Sep;149(11):8663-8671. doi: 10.1007/s00432-023-04806-y. Epub 2023 Apr 28.
4
Imaging features of SMARCA4-deficient thoracic sarcomas: a multi-centric study of 21 patients.SMARCA4 缺陷型胸肉瘤的影像学特征:21 例患者的多中心研究。
Eur Radiol. 2019 Sep;29(9):4730-4741. doi: 10.1007/s00330-019-06017-x. Epub 2019 Feb 14.
5
Diagnosis of thoracic SMARCA4-deficient undifferentiated tumor in cytology.诊断细胞学中胸 SMARCA4 缺陷型未分化肿瘤。
Cancer Cytopathol. 2023 Aug;131(8):526-534. doi: 10.1002/cncy.22709. Epub 2023 Jun 6.
6
Thorahcic SMARCA4-deficient undifferentiated tumors with ganglioneuroma and enchondroma: implications for SLC7A11 and ARID1A expression: a case report.伴有神经节神经瘤和内生软骨瘤的胸椎SMARCA4缺陷未分化肿瘤:对SLC7A11和ARID1A表达的影响:一例报告
Diagn Pathol. 2022 Feb 12;17(1):29. doi: 10.1186/s13000-022-01205-8.
7
[Clinical characteristics and prognosis analysis of 17 cases of SMARCA4-deficient chest tumors].17例SMARCA4缺陷型胸部肿瘤的临床特征及预后分析
Zhonghua Jie He He Hu Xi Za Zhi. 2024 Apr 12;47(4):325-331. doi: 10.3760/cma.j.cn112147-20230927-00202.
8
[Thoracic -deficient undifferentiated tumor-pathological diagnosis and combined immune checkpoint inhibitor treatment].[胸段发育不全性未分化肿瘤——病理诊断及免疫检查点抑制剂联合治疗]
Beijing Da Xue Xue Bao Yi Xue Ban. 2023 Apr 18;55(2):351-356. doi: 10.19723/j.issn.1671-167X.2023.02.022.
9
Dynamic and Static F-FDG PET/CT Imaging in SMARCA4-Deficient Non-Small Cell Lung Cancer and Response to Therapy: A Case Report.SMARCA4缺陷型非小细胞肺癌的动态与静态F-FDG PET/CT成像及治疗反应:病例报告
Diagnostics (Basel). 2023 Jun 13;13(12):2048. doi: 10.3390/diagnostics13122048.
10
Immune-Desert Tumor Microenvironment in Thoracic SMARCA4-Deficient Undifferentiated Tumors with Limited Efficacy of Immune Checkpoint Inhibitors.免疫荒漠型肿瘤微环境在胸内 SMARCA4 缺陷型未分化肿瘤中,免疫检查点抑制剂疗效有限。
Oncologist. 2022 Jun 8;27(6):501-511. doi: 10.1093/oncolo/oyac040.

引用本文的文献

1
deficiency: implications for non-small cell lung cancer and management strategies, with relevance to and distinctions from thoracic undifferentiated tumor.缺乏:对非小细胞肺癌的影响及管理策略,与胸段未分化肿瘤的关联及区别
Transl Lung Cancer Res. 2025 Apr 30;14(4):1456-1470. doi: 10.21037/tlcr-24-927. Epub 2025 Apr 24.
2
SMARCA4-deficient non-small cell lung cancer with metastasis to the sigmoid colon: a case report.转移至乙状结肠的SMARCA4缺陷型非小细胞肺癌:一例报告
World J Surg Oncol. 2025 Mar 29;23(1):106. doi: 10.1186/s12957-025-03757-7.
3
/BRG1-deficient non-small cell lung cancer: clinical, imaging, pathological features, and follow-up results of 23 patients.

本文引用的文献

1
Promising efficacy of immune checkpoint inhibitor plus chemotherapy for thoracic SMARCA4-deficient undifferentiated tumor.免疫检查点抑制剂联合化疗治疗胸部 SMARCA4 缺陷型未分化肿瘤的疗效有希望。
J Cancer Res Clin Oncol. 2023 Sep;149(11):8663-8671. doi: 10.1007/s00432-023-04806-y. Epub 2023 Apr 28.
2
SMARCA4: Current status and future perspectives in non-small-cell lung cancer.SMARCA4:非小细胞肺癌的现状与未来展望
Cancer Lett. 2023 Feb 1;554:216022. doi: 10.1016/j.canlet.2022.216022. Epub 2022 Nov 28.
3
SMARCA4-deficient lung carcinoma is an aggressive tumor highly infiltrated by FOXP3+ cells and neutrophils.
BRG1缺陷型非小细胞肺癌:23例患者的临床、影像学、病理特征及随访结果
Transl Lung Cancer Res. 2025 Jan 24;14(1):107-123. doi: 10.21037/tlcr-24-567. Epub 2025 Jan 22.
4
The impact of SMARCA4 loss in non-small cell lung cancer therapy.SMARCA4缺失在非小细胞肺癌治疗中的影响。
Heliyon. 2024 Dec 12;11(1):e41128. doi: 10.1016/j.heliyon.2024.e41128. eCollection 2025 Jan 15.
5
A Rare Case of Thoracic SMARCA4-Deficient Undifferentiated Tumor With Diffuse Brain Metastasis.1例罕见的伴有弥漫性脑转移的胸段SMARCA4缺陷型未分化肿瘤
Cureus. 2024 May 30;16(5):e61367. doi: 10.7759/cureus.61367. eCollection 2024 May.
SMARCA4 缺陷型肺癌是一种侵袭性肿瘤,大量浸润 FOXP3+ 细胞和中性粒细胞。
Lung Cancer. 2022 Jul;169:13-21. doi: 10.1016/j.lungcan.2022.05.001. Epub 2022 May 5.
4
CT findings of basaloid squamous cell carcinoma of the lung in 12 patients: A distinct category of squamous cell carcinoma in 2015 WHO classification of lung tumors.12 例肺基底细胞样鳞状细胞癌的 CT 表现:2015 年肺肿瘤 WHO 分类中一种独特的鳞状细胞癌类型。
Medicine (Baltimore). 2022 May 13;101(19):e29197. doi: 10.1097/MD.0000000000029197.
5
Immune-Desert Tumor Microenvironment in Thoracic SMARCA4-Deficient Undifferentiated Tumors with Limited Efficacy of Immune Checkpoint Inhibitors.免疫荒漠型肿瘤微环境在胸内 SMARCA4 缺陷型未分化肿瘤中,免疫检查点抑制剂疗效有限。
Oncologist. 2022 Jun 8;27(6):501-511. doi: 10.1093/oncolo/oyac040.
6
Managing Resistance to Immune Checkpoint Inhibitors in Lung Cancer: Treatment and Novel Strategies.肺癌中免疫检查点抑制剂耐药的管理:治疗方法与新策略
J Clin Oncol. 2022 Feb 20;40(6):598-610. doi: 10.1200/JCO.21.01845. Epub 2022 Jan 5.
7
First-Line Immunotherapy for Non-Small-Cell Lung Cancer.非小细胞肺癌的一线免疫治疗。
J Clin Oncol. 2022 Feb 20;40(6):586-597. doi: 10.1200/JCO.21.01497. Epub 2022 Jan 5.
8
Targeted Therapies for Lung Cancer Patients With Oncogenic Driver Molecular Alterations.针对具有致癌驱动分子改变的肺癌患者的靶向治疗。
J Clin Oncol. 2022 Feb 20;40(6):611-625. doi: 10.1200/JCO.21.01626. Epub 2022 Jan 5.
9
The 2021 WHO Classification of Lung Tumors: Impact of Advances Since 2015.2021 年世卫组织肺肿瘤分类:自 2015 年以来的进展影响。
J Thorac Oncol. 2022 Mar;17(3):362-387. doi: 10.1016/j.jtho.2021.11.003. Epub 2021 Nov 20.
10
TTF1-positive SMARCA4/BRG1 deficient lung adenocarcinoma.TTF1阳性的SMARCA4/BRG1缺陷型肺腺癌
J Pathol Transl Med. 2022 Jan;56(1):53-56. doi: 10.4132/jptm.2021.09.16. Epub 2021 Nov 16.